Jiangsu Bioperfectus Technologies Co., Ltd. (SHA:688399)
China · Delayed Price · Currency is CNY 65.08
-3.68 (-5.35%)
May 12, 2026, 3:00 PM CST
SHA:688399 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 326.02 | 339.05 | 331.36 | 380.05 | 4,336 | 2,340 |
Other Revenue | - | - | 18.25 | 23.13 | 1,199 | 499.11 |
| 326.02 | 339.05 | 349.61 | 403.18 | 5,535 | 2,839 | |
Revenue Growth (YoY) | -6.88% | -3.02% | -13.29% | -92.72% | 94.95% | 63.19% |
Cost of Revenue | 118.82 | 124.92 | 147.64 | 253.94 | 2,380 | 879.96 |
Gross Profit | 207.2 | 214.13 | 201.97 | 149.24 | 3,155 | 1,959 |
Selling, General & Admin | 204.66 | 211.03 | 214.27 | 377.62 | 720.25 | 534.41 |
Research & Development | 74.5 | 78.72 | 100.52 | 135.39 | 185.32 | 106.35 |
Other Operating Expenses | -10.25 | -16.66 | -7.42 | -8.87 | 17.48 | -5.25 |
Operating Expenses | 268.91 | 273.1 | 270.92 | 533.52 | 981.87 | 648.43 |
Operating Income | -61.71 | -58.97 | -68.95 | -384.28 | 2,173 | 1,311 |
Interest Expense | - | - | -7.75 | -6.94 | -5.33 | -3.96 |
Interest & Investment Income | 7.39 | 6.98 | 39.78 | 57.56 | 42.74 | 26.83 |
Earnings From Equity Investments | - | - | - | - | - | -2.74 |
Currency Exchange Gain (Loss) | - | - | 1.1 | -1.19 | 0.76 | -1.53 |
Other Non Operating Income (Expenses) | 22.75 | 11.73 | -0.49 | -0.16 | -0.33 | -3.33 |
EBT Excluding Unusual Items | -31.57 | -40.26 | -36.31 | -335.02 | 2,211 | 1,326 |
Gain (Loss) on Sale of Investments | 51.32 | 47.56 | 0.83 | 13.12 | 48.15 | 32.19 |
Gain (Loss) on Sale of Assets | 0.44 | 0.1 | 2.07 | -2.92 | -1.44 | 2.97 |
Asset Writedown | -39.56 | -39.46 | -9.33 | -79.01 | -140.31 | - |
Other Unusual Items | - | - | 46.93 | 28.16 | 21.76 | 30.72 |
Pretax Income | -19.36 | -32.06 | 4.19 | -375.67 | 2,139 | 1,392 |
Income Tax Expense | 13.42 | 9.02 | 6.19 | -1.86 | 310.81 | 198.56 |
Net Income | -32.78 | -41.08 | -2 | -373.81 | 1,828 | 1,193 |
Net Income to Common | -32.78 | -41.08 | -2 | -373.81 | 1,828 | 1,193 |
Net Income Growth | - | - | - | - | 53.19% | 45.59% |
Shares Outstanding (Basic) | 84 | 84 | 99 | 87 | 87 | 87 |
Shares Outstanding (Diluted) | 84 | 84 | 99 | 87 | 87 | 87 |
Shares Change (YoY) | -16.12% | -14.98% | 13.71% | -0.06% | 0.03% | -0.03% |
EPS (Basic) | -0.39 | -0.49 | -0.02 | -4.31 | 21.07 | 13.76 |
EPS (Diluted) | -0.39 | -0.49 | -0.02 | -4.31 | 21.07 | 13.76 |
EPS Growth | - | - | - | - | 53.14% | 45.64% |
Free Cash Flow | -70.19 | -34.11 | 83.06 | -224.48 | 1,614 | 681.91 |
Free Cash Flow Per Share | -0.84 | -0.41 | 0.84 | -2.59 | 18.60 | 7.86 |
Dividend Per Share | - | - | - | - | - | 6.757 |
Dividend Growth | - | - | - | - | - | 42.86% |
Gross Margin | 63.55% | 63.16% | 57.77% | 37.02% | 56.99% | 69.01% |
Operating Margin | -18.93% | -17.39% | -19.72% | -95.31% | 39.26% | 46.16% |
Profit Margin | -10.05% | -12.12% | -0.57% | -92.72% | 33.03% | 42.03% |
Free Cash Flow Margin | -21.53% | -10.06% | 23.76% | -55.68% | 29.16% | 24.02% |
EBITDA | -11.11 | -8.61 | -19.59 | -315.5 | 2,256 | 1,344 |
EBITDA Margin | -3.41% | -2.54% | -5.60% | -78.25% | 40.76% | 47.35% |
D&A For EBITDA | 50.6 | 50.35 | 49.36 | 68.78 | 83.4 | 33.63 |
EBIT | -61.71 | -58.97 | -68.95 | -384.28 | 2,173 | 1,311 |
EBIT Margin | -18.93% | -17.39% | -19.72% | -95.31% | 39.26% | 46.16% |
Effective Tax Rate | - | - | 147.81% | - | 14.53% | 14.27% |
Revenue as Reported | - | - | 349.61 | 403.18 | 5,535 | 2,839 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.